Approved in EU
Defitelio®▼ (defibrotide) is licensed in the European Union for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one month of age undergoing hematopoietic stem cell transplantation therapy.
Click here for additional product information.
▼This medicine is under additional monitoring.
More General News
More Financial News
In case of any side effects following the use of our drugs, please contact us
In caso di effetto/i indesiderato/i successivamente all’utilizzo di uno dei nostri farmaci, contattaci
View all Contacts
Gentium S.p.A. is a
Jazz Pharmaceuticals company.
To learn more about Jazz Pharmaceuticals, click here
Gentium S.p.A. - P.IVA n. 02098100130
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.